Roche reported encouraging results from two late-stage studies, but key outcomes remain pending as more than 70,000 Minnesota patients face possible coverage disruption.
Roche reported encouraging results from two late-stage drug studies, but key questions remain about long-term outcomes, regulatory review and patient access. Separately, more than 70,000 Minnesota community-health-center patients could risk losing coverage as federal insurance policies change beginning Jan. 1, MPR News reported.
The studies show the gap between a promising clinical result and treatment patients can obtain. A medicine must demonstrate benefit, clear regulatory review and be covered by insurers; even then, its price can shape access. The supplied reports do not provide pricing or coverage details for either Roche drug.
Pharmaphorum reported Oct. 24 that Roche’s phase 3 IMpower150 study found Tecentriq, Avastin and chemotherapy extended survival compared with Avastin and chemotherapy in advanced non-small-cell lung cancer. The combination reduced the risk of disease worsening or death by 38%. An interim overall-survival benefit, however, was not yet statistically significant.
That qualification matters. A reduction in the risk of progression or death is a trial finding, but it does not establish a statistically significant overall-survival benefit. Nor do the reported results establish a new FDA approval or insurance coverage. The available information does not say how much longer patients lived, what a treatment course might cost or whether coverage decisions will change.
Roche also announced results from its 459-person phase 3 IMAgINATION study of investigational sefaxersen. StockTitan reported Oct. 24 that the drug reduced proteinuria by 43.1% versus placebo at week 37. The study remains blinded and will assess kidney function at week 105. The interim finding does not determine whether the drug will preserve kidney function over the longer term, and the supplied material does not report an FDA approval.
Roche’s commercial scale provides context, but not a measure of patient affordability. Ad-Hoc-News reported that the company’s nine-month 2026 group sales rose 6% at constant exchange rates to 46.5 billion Swiss francs. Those sales figures do not show what patients pay for a specific medicine or whether insurers will cover it.
The immediate coverage concern is in Minnesota. MPR News reported Oct. 23 that more than 70,000 community-health-center patients could risk losing coverage because of expiring Affordable Care Act tax credits, new Medicaid work requirements and more frequent eligibility checks beginning Jan. 1. The figure describes people potentially at risk, not confirmed losses. The report did not break down how many might be affected by each change or what alternatives they could use.
For patients who depend on regular appointments and prescriptions, a coverage gap can affect access to care. The report does not identify specific treatments at risk, but its estimate makes the transition a significant local concern. Timely information about eligibility and practical ways to maintain coverage will matter as the changes approach.
A separate health update involving WWE Hall of Famer Ric Flair offers a personal account of illness but no broader evidence about hospital access. Charlotte Flair said Oct. 23 that her father was expected to be okay after a fall. Reports cited cuts to his head and eye; whether he suffered a concussion and when he would be discharged remained unconfirmed as of Oct. 24. Flair had also said a blood clot limited travel to three or four hours and that he was scheduled for a procedure to strip the affected vein.
For Roche, the next evidence milestones include the lung-cancer trial’s overall-survival analysis and the kidney study’s week-105 assessment. For Minnesota patients, the near-term question is whether coverage can be maintained as Jan. 1 approaches. In both cases, measured outcomes matter—but so does whether patients can access the care those outcomes may eventually support.
Susan Carter serves as a Senior Correspondent for Just Right News, where she leads the network’s comprehensive coverage of Health, Medicine, and Public Policy. With a career dedicated to dissecting the complexities of the American healthcare system, Susan brings a principled perspective to the most pressing debates of the day. Her reporting is characterized by a commitment to individual liberty, fiscal responsibility, and a healthy skepticism of government overreach, making her a vital voice for audiences seeking clarity in an increasingly regulated landscape.
Raised in Minneapolis, Minnesota, Susan’s professional outlook is deeply informed by the values of the American heartland. Growing up in the Twin Cities, she witnessed firsthand the importance of community-driven solutions and the resilience of the individual. This Midwestern foundation instilled in her a firm belief that the best answers to public policy challenges often come from local innovation and personal responsibility rather than top-down federal mandates. Her background allows her to translate complex legislative jargon into stories that resonate with families who value common sense and local autonomy.
Now based in Baltimore, Maryland, Susan operates from a unique vantage point at the intersection of medical innovation and urban policy. Living and working in a city renowned for its world-class medical institutions and significant public health challenges, she has a front-row seat to the realities of the modern healthcare landscape. Her proximity to these hubs of research and policy allows her to scrutinize how government intervention affects the quality of care and the freedom of medical professionals. In Baltimore, she sees the tangible results of policy decisions, using the city as a lens through which to examine the broader national health debate and the impact of federal spending on local communities.
As the lead for the acclaimed feature series “The Cost of Care,” Susan dives deep into the economic realities facing patients and providers alike. Her work focuses on the necessity of price transparency, the benefits of market competition, and the preservation of the sacred doctor-patient relationship. She is a staunch advocate for the idea that a well-informed public is the best defense against bureaucratic inefficiency. Through this series, she has exposed the hidden drivers of rising medical expenses, always seeking to empower the individual consumer over the massive institution.
Susan’s reporting on public policy is characterized by a commitment to rigorous inquiry and a focus on constitutional limits. Whether she is analyzing new pharmaceutical regulations, investigating the impact of federal health mandates, or exploring the future of medical technology, her goal remains the same: to provide Just Right News audiences with the facts they need to navigate a complex world. By blending her Midwestern sensibilities with the insights gained from her base in Maryland, Susan Carter has become a trusted authority for those who believe that personal freedom and public health are inextricably linked. Her work continues to challenge the status quo, advocating for a system that respects the taxpayer and prioritizes the patient.